Bayer HealthCare sees strong growth in Q3 2015

Bayer HealthCare has delivered strong double-digit growth during the third quarter of 2015, according to the Bayer group's latest financial statement.

The group delivered a sales total of 11.04 billion euros (7.92 billion pounds) during the quarter, up by 10.7 percent year on year, as well as achieving earnings growth of 28 percent. This allowed Bayer to confirm its forecasts for the full year.

Its HealthCare division was a key driver of this performance, with sales up by 19.2 percent to 5.65 billion euros. The scale of this improvement can be partly attributed to the acquisition of a number of products from Merck Sharp and Dohme.

It also saw a further strong surge in sales for newer therapies such as the anticoagulant Xarelto, the eye medicine Eylea, the cancer drugs Stivarga and Xofigo, and the pulmonary hypertension treatment Adempas.

Bayer's management board chairman Dr Marijn Dekkers said: "This positive business development continued to be driven to a significant extent by our recently launched pharmaceutical products. Business expanded in all divisions of the consumer health segment."

The firm recently announced reorganisation of the structure of its life science business, to be implemented as of the start of next year, that will divide the company into pharmaceutical, consumer health and crop science divisions.